Clinical Trial: Bioavailability and Effectiveness of Transdermally Administered Morphine

This study is currently recruiting patients.
Verified by Alberta Cancer Board July 2005

Sponsors and Collaborators: Alberta Cancer Board
ACB Palliative Care Research Initiative
Information provided by: Alberta Cancer Board
ClinicalTrials.gov Identifier: NCT00125684

Purpose

Patients will participate in two arms of the trial, one of which will be morphine administered transdermally, and after a 3 day wash out period, morphine administered subcutaneously. Blood draws will be done after both dosing in order to comapre blood legels of morphine by the different routes.
Condition Intervention Phase
Cancer related pain
Stable Baseline Pain
Currently Taking Opioids
 Drug: morphine
Phase I

MedlinePlus consumer health information 

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Bio-availability Study

Further Study Details: 
Primary Outcomes: detectable morphine levels in serum
Expected Total Enrollment:  6

Study start: July 2003;  Expected completion: July 2007
Last follow-up: July 2007;  Data entry closure: July 2007

Patients will participate in two arms of the trial, one of which will be morphine administered transdermally, and after a 3 day wash out period, morphine administered subcutaneously. Blood draws will be done after both dosing in order to comapre blood legels of morphine by the different routes

Eligibility

Ages Eligible for Study:  18 Years   -   65 Years,  Genders Eligible for Study:  Both
Criteria

Inclusion Criteria:

  • chronic cancer pain minimum baseline pain of 3/10 no change in medications over 3 days prior to study period ability to give informed consent willingness to undergo repeated blood sampling

Exclusion Criteria:

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00125684

Carla Stiles      403-210-8243    carla.stiles@calgaryhealthregion.ca

Canada, Alberta
      Tom Baker Cancer Centre, Calgary,  Alberta,  T2N 4N2,  Canada; Recruiting
Rachel Syme, PhD

Study chairs or principal investigators

Neil Hagen,  Principal Investigator,  Alberta Cancerboard   

More Information

Study ID Numbers:  10181
Last Updated:  August 1, 2005
Record first received:  August 1, 2005
ClinicalTrials.gov Identifier:  NCT00125684
Health Authority: Canada: Health Canada
ClinicalTrials.gov processed this record on 2005-08-02

Resources




Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us